GlobeNewsWire
02 Oct 2026, 05:00 UTC · 1w ago
Impact · against what's priced in
The management changes at Addex Therapeutics are marginally positive, as the appointment of an executive with a track record of Phase II successes provides a catalyst for clinical progression. However, because there is no detailed priced-in reconstruction for ADXN, the exact impact relative to current valuation is uncertain.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Addex Therapeutics has appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management.
Newpress release dated October 2, 2026
So whatRocher's history of advancing two candidates into Phase II suggests a higher probability of clinical milestones in the next 12-24 months.
More positive than 68% of claims this week
Continue reading
5 related stories
The price's assumptions are unknown as no reconstruction is on file; however, hiring Jean-Philippe Rocher, who previously advanced two candidates to Phase II, increases the probability of hitting near-term clinical milestones.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
Addex recently regained the rights to its GABAB PAM program from Indivior.
Priced inreferred to as having already happened
More positive than 56% of claims this week
Mikhail Kalinichev has stepped down as Head of Translational Science to focus on his role at Neurosterix.
Newpress release dated October 2, 2026
More negative than 62% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company is appointing a highly experienced former executive to guide its next clinical phase and has regained rights to a key program.
Near neutral — 92% of ticker scores this week are stronger
Mentioned only as a former employer of a new executive.
Near neutral — 92% of ticker scores this week are stronger
Mentioned as a licensing partner and former rights holder, but no material sentiment impact provided.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
4h ago
−11.1%
Price is moving against the score
$2.65 vs $2.98 close before publication (Oct 1) · not market-adjusted
ADXN chart →
